Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this newly discovered class of gene expression repressors may be viable therapeutic targets. A microarray of miRNA changes in ALS-model superoxide dismutase 1 (SOD1)(G93A) rodents identified 12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. To test miRNA inhibition in the central nervous system (CNS) as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs throughout the CNS and in the periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and, following intraventricular delivery, demonstrated widespread functional distribution in the brain and spinal cord. After treating SOD1(G93A) mice with anti-miR-155, we significantly extended survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155 is a promising new therapeutic target for human ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“miRNAs are increasingly recognized as key regulators in ALS pathophysiology, including mitochondrial integrity and neuroinflammation, with miR-155 and miR-206 demonstrating pivotal roles in SOD1G93A models [48,49,50,51].”
From Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis (2026) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inhibiting miR-155 significantly delays disease progression in SOD1 G93A mice (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Work from our lab and others found that miR-155, a glialenriched miRNA, is upregulated in the spinal cords of end-stage ALS model (SOD1 G93A ) mice and human autopsy (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
In the citing paper
“Targeting miR-155 in microglia has shown to be a benefit in models of ALS84,195 and is currently being pursued as a possible therapeutic strategy.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948 · cited 1×
“Since their discovery in 1993 (1), microRNAs (miRNAs) have emerged as key regulators in numerous physiological and pathological processes.”
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204 · cited 1×
“Anti-miRs have been used safely and effectively in the periphery in recent human clinical trials [NCT00688012 and NCT00979927 (20)], and CSF infusion of antisense oligonucleotides designed to lower mRNA has recently been applied to patients with ALS (21).”
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826 · cited 3×
“Furthermore, quantification of one of these targets, SHIP1, across the CNS demonstrated a significant increase over saline in all areas assayed (Fig.”
microRNA-155 Regulates the Generation of Immunoglobulin Class-Switched Plasma Cells
Vigorito, E., Perks, K. L., Abreu-Goodger, C., Bunting, S., Xiang, Z., Kohlhaas, S., Das, P. P., Miska, E. A., Rodriguez, A., Bradley, A., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.009 · Cited by 763
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703 · cited 1×
“Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s Disease) is a fatal adult-onset neurodegenerative disease characterized by the selective loss of motor neurons in the spinal cord and brain leading to stiffness, severe muscle weakness and death because of respiratory failure typically within 3–5 years of…”
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationJunker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., Wekerle, H., Hohlfeld, R., & Meinl, E. (2009) · Brain · doi:10.1093/brain/awp300 · Cited by 595 · cited 1×
“Our data clearly identify miR-155 as a promising therapeutic target for ALS and may potentially apply more broadly to neurological disorders where miR-155 is increased including multiple sclerosis (23) and in glioblastoma (24).”
Research works printed but not linked: 2
- Esau, C. (2010) In: Keystone Symposia: Diabetes (Z6). Whistler: British Columbia Canada.
- D'Urso, P.I., D'Urso, O.F., Storelli, C., Mallardo, M., Gianfreda, C.D., Montinaro, A., Cimmino, A., Pietro, C. and Marsigliante, S. (2012) miR-155 4134 Human Molecular Genetics, 2013, Vol. 22, No. 20
Cited by
Items 201–243 of 243
Shamsuzzama, S., Kumar, L., Haque, R., & Nazir, A. (2018) · Springer eBooks · doi:10.1007/978-981-13-1699-9_2 · Cited by 1
RNA Metabolism and Therapeutics in Amyotrophic Lateral Sclerosis
Pansarasa, O., Gagliardi, S., Sproviero, D., & Cereda, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90704 · Cited by 2
“miRNA155 was evaluated in CD14+ CD16− monocytes [55] and spinal cords of ALS patients, and it increases both in fALS and sALS [59].”
BackgroundMethodAstrocyte-Neuron Interactions Contributing to Amyotrophic Lateral Sclerosis Progression
Jensen, B. K. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-64839-7_12 · Cited by 2
Three Neurodegenerative Diseases: A Single Hope
Youssef, S. H., Atalah, H. N., Badawy, M. T., El‐Fawal, H. A. N., & Salama, M. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_3 · Cited by 3
Antisense Oligonucleotides for Amyotrophic Lateral Sclerosis
Smith, S., & Miller, T. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89307-0_11 · Cited by 1
Self-citationAntisense Oligonucleotides for Amyotrophic Lateral Sclerosis
Self, W. K., & Miller, T. M. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_6 · Cited by 1
Self-citationTiny microRNAs Fine-Tune Amyotrophic Lateral Sclerosis Regulation
Bhadra, U., Pal, A., Chhatai, J., & Bhadra, M. P. (2016) · InTech eBooks · doi:10.5772/63528
“miR-155 expression can be efficiently inhibited by anti-miR delivery to the CNS and periphery of SOD1-G93A mouse [86].”
BackgroundMicroRNAS: Mapping out the road to amyotrophic lateral sclerosis
Rad, N., & Weiss, M. D. (2018) · Muscle & Nerve · doi:10.1002/mus.26141
“While not yet tested in ALS patients, antisense therapy directed to miR-155 when given to the ALS-SOD1 mice has been shown to extend survival.(8) While preliminary, these studies suggest that miRNA specific targeting could be developed into disease modifying therapy.”
BackgroundHussein, H. A., Gomaa, M., Deibert, R. J., Fisher, L. C., Amici, S. A., Guerau‐de‐Arellano, M., Basso, M. D., & Behery, A. (2018) · Slovenian Veterinary Research · doi:10.26873/svr-634-2018
“In the CNS, miR155 is implicated in the pathogenesis of SCI, stroke, multiple sclerosis, amylotrophic lateral sclerosis, encephalomyelitis and Alzheimer’s disease (14-17,29,30).”
BackgroundmiRNAs as therapeutic agents in neurodegeneration : a pilot study
Parsi, S. (2016) · Corpus Université Laval (Université Laval) · Cited by 4
Hawley, Z. C. E. (2020) · Scholarship@Western (Western University) · Cited by 1
Development of secretome-based therapy by motor neuron modulation of miRNA-124 in ALS mouse models
Morais, H. M. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Emerging Roles of Non-Coding RNA in Neuronal Function and Dysfunction
Fagan, S. G., & Pfeiffer, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101327 · Cited by 1
“Upregulation of miR-155 has been identified in both sporadic and familial ALS, and its inhibition in SOD1 mutant mice resulted in increased survival [114].”
BackgroundPatil, K. S., & Møller, S. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-31143-2_58-1
A potential therapeutic effect of miR-155 downregulation in an experimental model of demyelination
Elfetiany, O. S., Abdelgawad, H., Azhary, N. E., Abdelmonsif, D. A., Achy, S. E., & Hegazy, M. A. (2022) · The Annals of Clinical and Analytical Medicine · doi:10.4328/acam.21203
Antisense Oligonucleotide Therapy Against SCA3
McLoughlin, H. S. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_16
Three Neurodegenerative Diseases: A Single Hope
Youssef, S. H., Atalah, H. N., Badawy, M. T., El‐Fawal, H. A. N., & Salama, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-3949-5_3-1
Sarkar, S., Pandey, A. K., Khan, B., & Pant, A. B. (2025) · BMC Genomics · doi:10.1186/s12864-025-11970-7 · Cited by 1
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592644
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592668
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592653
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592665
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592647
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592650
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592662
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y. H., Kim, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12592656
Testing miRNA-cell based strategies to obtain therapeutic secretomes for spinal ALS
Martins, N. B. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Izražanje izbranih nekodirajočih RNA pri bolnikih z amiotrofično lateralno sklerozo
Dolinar, A. (2020) · Repository of the University of Ljubljana (University of Ljubljana)
de la Torre Sebastián, M., Toivonen, J. M., & Osta Pinzolas, R. (2021) · Zaguan (Universidad de Zaragoza) · Cited by 2
Koley, R., De, S., Ghosh, A., Bhattacharjee, D., Mitra, A., Mondal, B., Pahari, A., Nandi, M., Kanri, R., Dasgupta, S., et al. (2026) · In vitro models · doi:10.1007/s44164-026-00111-3
Étude des microARNs dans les vésicules extracellulaires microgliales : signatures et neuroprotection
Lemaire, Q. (2019) · theses.fr (ABES) · doi:10.70675/3a61ee49zc6e9z4a3cz9e2dzb1c527312127
Convergent RNA Pathophysiology in Amyotrophic Lateral Sclerosis
Patterson, H. (2026) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/y1nh-c204
The dual face of miR-146a in ALS
Haim, G., & Hornstein, E. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2617170123
Jin, T., Yang, B., Cai, Z., Zhang, H., & Wang, T. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s622530
“54 These findings do not demonstrate that peripheral EV-associated miR-155 enters the CNS or induces a discrete pro-inflammatory microglial state.”
Benchohra, A., Juárez-Alia, C., Serrano‐Heras, G., Segura, T., Peinado, J. R., & Rabanal‐Ruiz, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219506
Metadata
- Authors
- Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M.
- Affiliations
- Washington University in St. Louis (US)
- Regulus Therapeutics (United States) (US)
- Corresponding author
- Miller, Timothy M.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-04
- Volume
- 22
- Issue
- 20
- Pages
- 4127-4135
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3781640
- OpenAlex
- W2106430667
- Cited by
- 236
- References
- 27
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 11 · 2023: 15 · 2022: 11 · 2021: 15 · 2020: 29 · 2019: 13 · 2018: 30 · 2017: 22 · 2016: 17 · 2015: 27 · 2014: 19 · 2013: 2
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dana Foundation
- Massachusetts General Hospital
- Edward Mallinckrodt, Jr. Foundation
- National Institutes of Health
- School of Medicine, Stanford University
- National Institute of Neurological Disorders and Stroke (F31NS077781, K08NS062138, K08NS074194, R01NS078398)
- Robert Packard Center for ALS Research, Johns Hopkins University
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- miR-155, amyotrophic lateral sclerosis, anti-miR oligonucleotides, microRNA inhibition, SOD1 G93A mice, survival extension, peritoneal macrophages, spinal cord, therapeutic target, antisense oligonucleotides
- MeSH terms
- Adult, Aged, Amyotrophic Lateral Sclerosis, Animals, Brain, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Spinal Cord, Superoxide Dismutase, Case-Control Studies, Oligonucleotides, Antisense, MicroRNAs, Mice, Rats, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.